These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38739228)

  • 1. Determination of promising inhibitors for N-SH2 domain of SHP2 tyrosine phosphatase: an in silico study.
    Gencer Akçok EB; Güner H; Akçok İ
    Mol Divers; 2024 May; ():. PubMed ID: 38739228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An In Silico Study Investigating Camptothecin-Analog Interaction with Human Protein Tyrosine Phosphatase, SHP2 (PTPN11).
    Bajia D; Derwich K
    Pharmaceuticals (Basel); 2023 Jun; 16(7):. PubMed ID: 37513838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
    Anselmi M; Calligari P; Hub JS; Tartaglia M; Bocchinfuso G; Stella L
    J Chem Inf Model; 2020 Jun; 60(6):3157-3171. PubMed ID: 32395997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
    Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM
    J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the Allosteric Mechanism of Src Homology-2 Domain-Containing Protein Tyrosine Phosphatase 2 (SHP2) by Molecular Dynamics Simulations.
    Wang Q; Zhao WC; Fu XQ; Zheng QC
    Front Chem; 2020; 8():597495. PubMed ID: 33330386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state.
    Calligari P; Santucci V; Stella L; Bocchinfuso G
    Comput Struct Biotechnol J; 2021; 19():6125-6139. PubMed ID: 34900129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intramolecular Interaction with the E6 Region Stabilizes the Closed Conformation of the N-SH2 Domain and Concurs with the Self-Inhibitory Docking in Downregulating the Activity of the SHP2 Tyrosine Phosphatase: A Molecular Dynamics Study.
    Bellacchio E
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
    Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
    Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains.
    Sha F; Gencer EB; Georgeon S; Koide A; Yasui N; Koide S; Hantschel O
    Proc Natl Acad Sci U S A; 2013 Sep; 110(37):14924-9. PubMed ID: 23980151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathogenic T42A mutation in SHP2 rewires the interaction specificity of its N-terminal regulatory domain.
    van Vlimmeren AE; Voleti R; Chartier CA; Jiang Z; Karandur D; Humphries PA; Lo WL; Shah NH
    bioRxiv; 2024 Apr; ():. PubMed ID: 37502916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The loops of the N-SH2 binding cleft do not serve as allosteric switch in SHP2 activation.
    Anselmi M; Hub JS
    Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33888588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revealing Allostery in PTPN11 SH2 Domains from MD Simulations.
    Anselmi M; Hub JS
    Methods Mol Biol; 2023; 2705():59-75. PubMed ID: 37668969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a novel SHP2 allosteric inhibitor using virtual screening, FMO calculation, and molecular dynamic simulation.
    Yuan Z; Zhang M; Chang L; Chen X; Ruan S; Shi S; Zhang Y; Zhu L; Li H; Li S
    J Mol Model; 2024 Apr; 30(5):131. PubMed ID: 38613643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain-containing protein tyrosine phosphatase (SHP2) inhibitor at molecular level through molecular docking and molecular dynamics.
    Wang RR; Liu WS; Zhou L; Ma Y; Wang RL
    J Biomol Struct Dyn; 2020 Mar; 38(5):1525-1538. PubMed ID: 31043123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphopeptide binding to the N-SH2 domain of tyrosine phosphatase SHP2 correlates with the unzipping of its central β-sheet.
    Marasco M; Kirkpatrick J; Carlomagno T; Hub JS; Anselmi M
    Comput Struct Biotechnol J; 2024 Dec; 23():1169-1180. PubMed ID: 38510972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of allosteric SHP2 inhibitors through ensemble-based consensus molecular docking, endpoint and absolute binding free energy calculations.
    Jama M; Ahmed M; Jutla A; Wiethan C; Kumar J; Moon TC; West F; Overduin M; Barakat KH
    Comput Biol Med; 2023 Jan; 152():106442. PubMed ID: 36566625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
    Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
    Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors.
    Song Y; Zhao M; Wu Y; Yu B; Liu HM
    Acta Pharm Sin B; 2021 Mar; 11(3):750-762. PubMed ID: 33777680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting protein tyrosine phosphatase to unravel possible inhibitors for Streptococcus pneumoniae using molecular docking, molecular dynamics simulations coupled with free energy calculations.
    Zaman Z; Khan S; Nouroz F; Farooq U; Urooj A
    Life Sci; 2021 Jan; 264():118621. PubMed ID: 33164832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
    Fragale A; Tartaglia M; Wu J; Gelb BD
    Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.